Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200593 | 0.85 | CYP3A4 (0.42) | CYP3A4DRD1FLT3KDM4ENPC1 | |
| SCHEMBL4368644 | 0.82 | CYP3A4 (0.68) | CYP3A4GPR119FLT3PIK3CACYP2C9 | |
| SCHEMBL1128588 | 0.81 | CYP3A4 (0.70) | CYP3A4GPR119FLT3PIK3CACYP2C9 | |
| SCHEMBL1128902 | 0.79 | CYP3A4 (0.75) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL2017732 | 0.78 | CYP3A4 (0.69) | CYP3A4GPR119FLT3CYP2C9 | |
| SCHEMBL2019784 | 0.78 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL9006352 | 0.78 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL1128522 | 0.78 | CYP3A4 (0.75) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL1128844 | 0.77 | CYP3A4 (0.84) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL2021841 | 0.77 | CYP3A4 (0.67) | CYP3A4GPR119KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CYP3A4 1503/4885GPR119 1/4885ATR 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.